

Title (en)

A RECOMBINANT CELL LINE EXPRESSING GPCR α 11 AS A FUNCTIONAL RECEPTOR VALIDATED BY ANGIOPEPTIN AND USEFUL FOR SCREENING OF AGONISTS AND ANTAGONISTS

Title (de)

EINE REKOMBINANTE ZELLINIE, DIE GPCR α 11 EXPRIMIEREN UND DIE EINEN FUNKTIONELLEN REZEPTOR FÜR ANGIOPEPTIN DARSTELLT UND SICH FÜR DAS SCREENING VON AGONISTEN UND ANTAGONISTEN EIGNET

Title (fr)

LIGNEE CELLULAIRE RECOMBINEE EXPRIMANT GPCR α 11 EN TANT QUE RECEPTEUR FONCTIONNEL VALIDE PAR L'ANGIOPEPTINE ET UTILE DANS LE CRIBLAGE D'AGONISTES ET ANTAGONISTES

Publication

EP 1297003 A2 20030402 (EN)

Application

EP 01942923 A 20010620

Priority

- EP 01942923 A 20010620
- BE 0100104 W 20010620
- EP 01870015 A 20010126
- EP 01870024 A 20010212
- US 21291300 P 20000620
- US 21749400 P 20000711

Abstract (en)

[origin: WO0198330A2] The present invention is related to a G-protein coupled receptor or GPCR α 11 similar to rat RTA receptor (37 %) and expressed in testis, thymus and uterus. Aequorin cell line expressing GPCR α 11 has been used for screening of tissue extracts and reference ligands. GPCR α 11 cells gave a specific signal with synthetic angiopeptin and a somatostatin analog allowing to validate this cell line for screening of natural or synthetic agonists and antagonists. In parallel, extended tissue distribution and polyclonal antibodies have been produced to facilitate GPCR α 11 characterisation.

IPC 1-7

C07K 14/00

IPC 8 full level

A01K 67/027 (2006.01); **A61K 45/00** (2006.01); **A61P 1/04** (2006.01); **A61P 1/08** (2006.01); **A61P 1/14** (2006.01); **A61P 3/04** (2006.01); **A61P 3/10** (2006.01); **A61P 7/10** (2006.01); **A61P 9/00** (2006.01); **A61P 9/02** (2006.01); **A61P 9/04** (2006.01); **A61P 9/10** (2006.01); **A61P 9/12** (2006.01); **A61P 9/14** (2006.01); **A61P 13/08** (2006.01); **A61P 17/02** (2006.01); **A61P 19/08** (2006.01); **A61P 19/10** (2006.01); **A61P 25/04** (2006.01); **A61P 25/06** (2006.01); **A61P 25/14** (2006.01); **A61P 25/16** (2006.01); **A61P 25/18** (2006.01); **A61P 25/22** (2006.01); **A61P 25/24** (2006.01); **A61P 25/28** (2006.01); **A61P 29/00** (2006.01); **A61P 31/04** (2006.01); **A61P 31/10** (2006.01); **A61P 31/12** (2006.01); **A61P 35/00** (2006.01); **A61P 35/04** (2006.01); **A61P 37/02** (2006.01); **A61P 37/08** (2006.01); **A61P 43/00** (2006.01); **C07K 14/00** (2006.01); **C07K 14/705** (2006.01); **C12N 1/15** (2006.01); **C12N 1/19** (2006.01); **C12N 1/21** (2006.01); **C12N 5/10** (2006.01); **C12N 15/09** (2006.01); **C12Q 1/02** (2006.01); **G01N 33/15** (2006.01); **G01N 33/50** (2006.01)

CPC (source: EP)

A61P 1/04 (2017.12); **A61P 1/08** (2017.12); **A61P 1/14** (2017.12); **A61P 3/04** (2017.12); **A61P 3/10** (2017.12); **A61P 7/10** (2017.12); **A61P 9/00** (2017.12); **A61P 9/02** (2017.12); **A61P 9/04** (2017.12); **A61P 9/10** (2017.12); **A61P 9/12** (2017.12); **A61P 9/14** (2017.12); **A61P 13/08** (2017.12); **A61P 17/02** (2017.12); **A61P 19/08** (2017.12); **A61P 19/10** (2017.12); **A61P 25/04** (2017.12); **A61P 25/06** (2017.12); **A61P 25/14** (2017.12); **A61P 25/16** (2017.12); **A61P 25/18** (2017.12); **A61P 25/22** (2017.12); **A61P 25/24** (2017.12); **A61P 25/28** (2017.12); **A61P 29/00** (2017.12); **A61P 31/04** (2017.12); **A61P 31/10** (2017.12); **A61P 31/12** (2017.12); **A61P 35/00** (2017.12); **A61P 35/04** (2017.12); **A61P 37/02** (2017.12); **A61P 37/08** (2017.12); **A61P 43/00** (2017.12); **C07K 14/705** (2013.01); **A01K 2217/05** (2013.01); **A01K 2217/075** (2013.01)

Citation (search report)

See references of WO 0198330A2

Designated contracting state (EPC)

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

DOCDB simple family (publication)

WO 0198330 A2 20011227; **WO 0198330 A3 20020502**; AU 6571701 A 20020102; CA 2413435 A1 20011227; EP 1297003 A2 20030402; JP 2004500125 A 20040108

DOCDB simple family (application)

BE 0100104 W 20010620; AU 6571701 A 20010620; CA 2413435 A 20010620; EP 01942923 A 20010620; JP 2002504285 A 20010620